Comparison of the Effects of the Direct Thrombin Inhibitor, Pradaxa, to That of Warfarin on Bone Mass and Bone Turnover Markers

Trial Profile

Comparison of the Effects of the Direct Thrombin Inhibitor, Pradaxa, to That of Warfarin on Bone Mass and Bone Turnover Markers

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2017.
    • 24 Mar 2017 Status changed from recruiting to discontinued due to low enrollment numbers.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top